Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant
Susan DeWolf, Steven J. Siegel, Joseph Schmalz, Wael Saber, Alexandre Albanese, Jiayi Dong, Michael J. Martens, Brent R. Logan, Lorenzo Iovino, Kayleigh Ingersoll Omdahl, Nicholas Winn, Edward Chen, James J. Kaminski, Donna S Neuberg, Kyle M. Hebert, Paula Keskula, Jillian Zavistaski, Lea Steinberg, Isabella Schichter, Zoe Katsamakis, Lorenzo S Cagnin, Vanessa A Hernandez, Makya Warren, Kristy Applegate, Merav Bar, Saurabh Chhabra, Sung Won Choi, William Clark, Suman R. Das, Robert R. Jenq, Richard John Jones, John E. Levine, Hemant S. Murthy, Armin Rashidi, Marcie Riches, Karamjeet Sandhu, Anthony Derek Sung, Karilyn T. M. Larkin, Monzr M. Al Malki, Mahasweta Gooptu, Hany Elmariah, Amin Majid Alousi, Lyndsey Runaas, Brian C. Shaffer, Andrew R. Rezvani, Najla El Jurdi, Alison Wakoff Loren, Danielle Scheffey, Catherine Miller Sanders, Mehdi Hamadani and 9 more
Peer-reviewed journalReal-world use
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
This study reveals how distinct immunosuppression strategies uniquely remodel T cell immunity and shape divergent transplant outcomes.
In conclusion, dabrafenib is a low–molecular weight compound that inhibits cavernoma pathogenesis, suggesting that CCMs could be treated with dabrafenib to block cavernoma growth and vascular leakage.
Maximiliano Arce, Hua Huang, Charlotte Rorsman and 13 more — Science Translational Medicine
Our results show that even the structurally minimal class A GPCRs are viable targets for de novo cyclic peptide discovery, highlighting the potential for uncovering ligands towards other members of the GPCR superfamily.
F. Salgado-Polo, M. Matic, P. B. Rainsford and 9 more — bioRxiv
Employing this assay, structure-based drug design by protein X-ray crystallography, structure-activity relationship (SAR) analyses, and in vitro and in vivo validation, we developed novel CYP8B1-specific small molecule inhibitors.
Z. Fang, A. R. L. Agua, J. Jossart and 17 more — bioRxiv
PreprintBold claims, read criticallyClaims a big stepReal-world use
We developed a humanized anti-ZIP12 monoclonal antibody, APL-9796, that normalized intracellular Zn 2+ concentration, suppressed proliferation in fibroblasts derived from patients with PAH and PDGF-stimulated PASMCs, and reduced PDGF-induced cytoskeletal remodeling in PASMCs and contractility in PASMCs and engineered pulmonary artery tissues.
Lan Zhao, Lan Zhao, Stephanie Hopley and 18 more — Science Translational Medicine
Peer-reviewed journalBold claims, read criticallyReal-world use